← Back to Search

Calcium Channel Blocker

Medical Therapy for Myocardial Bridging

Phase 2
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial tests beta blockers and calcium channel blockers on adults with chest pain and myocardial bridges but no blocked arteries. These medications may help by relaxing heart muscles and improving blood flow, potentially reducing chest pain. Beta blockers and calcium channel blockers have been shown to be effective in treating angina pectoris, often used in combination to enhance therapeutic effects.

Eligible Conditions
  • Myocardial Bridging
  • Coronary artery bridge

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo
Secondary study objectives
Changes in exercise capacity.
Other study objectives
Drug adherence.
Side effects.

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Beta Blocker (nebivolol)Active Control1 Intervention
Group II: Calcium Channel Blocker (diltiazem)Active Control1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,484 Previous Clinical Trials
17,515,761 Total Patients Enrolled
1 Trials studying Myocardial Bridging
150 Patients Enrolled for Myocardial Bridging

Media Library

Diltiazem (Calcium Channel Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT04130438 — Phase 2
Myocardial Bridging Research Study Groups: Beta Blocker (nebivolol), Calcium Channel Blocker (diltiazem), Placebo
Myocardial Bridging Clinical Trial 2023: Diltiazem Highlights & Side Effects. Trial Name: NCT04130438 — Phase 2
Diltiazem (Calcium Channel Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04130438 — Phase 2
~0 spots leftby Jan 2025